Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 3/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Celemics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩6,500.00 |
52 Week High | ₩10,400.00 |
52 Week Low | ₩2,745.00 |
Beta | 0 |
11 Month Change | 73.33% |
3 Month Change | 78.57% |
1 Year Change | 46.40% |
33 Year Change | -64.67% |
5 Year Change | n/a |
Change since IPO | -74.81% |
Recent News & Updates
Celemics (KOSDAQ:331920) Is Posting Solid Earnings, But It Is Not All Good News
Aug 26We're Not Very Worried About Celemics' (KOSDAQ:331920) Cash Burn Rate
Jul 29Here's Why We're Not Too Worried About Celemics' (KOSDAQ:331920) Cash Burn Situation
Mar 28Recent updates
Celemics (KOSDAQ:331920) Is Posting Solid Earnings, But It Is Not All Good News
Aug 26We're Not Very Worried About Celemics' (KOSDAQ:331920) Cash Burn Rate
Jul 29Here's Why We're Not Too Worried About Celemics' (KOSDAQ:331920) Cash Burn Situation
Mar 28What You Need To Know About Celemics, Inc.'s (KOSDAQ:331920) Investor Composition
Dec 17Shareholder Returns
A331920 | KR Life Sciences | KR Market | |
---|---|---|---|
7D | -30.5% | 2.5% | -0.2% |
1Y | 46.4% | 28.5% | 4.1% |
Return vs Industry: A331920 exceeded the KR Life Sciences industry which returned 28.5% over the past year.
Return vs Market: A331920 exceeded the KR Market which returned 4.1% over the past year.
Price Volatility
A331920 volatility | |
---|---|
A331920 Average Weekly Movement | 17.5% |
Life Sciences Industry Average Movement | 9.3% |
Market Average Movement | 6.5% |
10% most volatile stocks in KR Market | 12.2% |
10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A331920's share price has been volatile over the past 3 months.
Volatility Over Time: A331920's weekly volatility has increased from 11% to 17% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 39 | Young-hoon Lee | www.celemics.com |
Celemics, Inc. designs, manufactures, and distributes sequencing kits. The company offers BRCA, somatic mutation cancer, and hereditary cancer kits; and NGS Library preparation kits. It also provides customized target enrichment kit, next generation sequencing, NGS unit, and NGS-lab building consulting services.
Celemics, Inc. Fundamentals Summary
A331920 fundamental statistics | |
---|---|
Market cap | ₩53.07b |
Earnings (TTM) | ₩11.01b |
Revenue (TTM) | ₩6.08b |
4.8x
P/E Ratio8.7x
P/S RatioIs A331920 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A331920 income statement (TTM) | |
---|---|
Revenue | ₩6.08b |
Cost of Revenue | ₩3.65b |
Gross Profit | ₩2.43b |
Other Expenses | -₩8.58b |
Earnings | ₩11.01b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 1.35k |
Gross Margin | 39.98% |
Net Profit Margin | 181.03% |
Debt/Equity Ratio | 0% |
How did A331920 perform over the long term?
See historical performance and comparison